Canine dry eye (KCS) guide — Schirmer tear test ranges, FDA-approved Optimmune (cyclosporine) vs compounded tacrolimus, openFDA safety data, and treatment escalation.

Thick, yellow-green goop accumulating around a dog's eyes is a frequent complaint in veterinary clinics. While many owners assume their pet has a simple "eye infection" that can be cured with a short course of antibiotic drops, the reality is often far more complex. In many cases, the root cause is keratoconjunctivitis sicca (KCS), commonly known as dry eye.

Dry eye in dogs is a chronic, progressive inflammatory disease characterized by a deficiency in the aqueous (water) component of the tear film. Without adequate tear production, the cornea and conjunctiva become severely irritated, inflamed, and prone to painful ulcerations and scarring. Fortunately, KCS is highly manageable, but it requires a solid understanding of the diagnostic markers, the pharmacological differences between first-line and second-line treatments, and a commitment to lifelong therapy.

Quick answer

Canine dry eye (KCS) is most commonly an immune-mediated disease where the dog's own T-lymphocytes attack and destroy the tear-producing lacrimal glands. Diagnosis is confirmed using a Schirmer tear test (STT), which measures the millimeters of tear fluid absorbed by a specialized paper strip over 60 seconds. A normal result is greater than 15 mm/minute; values below 10 mm/minute indicate KCS, and values 5 mm/minute or lower indicate severe KCS.

The FDA-approved first-line medical treatment is Optimmune Ophthalmic Ointment (cyclosporine 0.2%) (NADA 141-052). Cyclosporine is a calcineurin inhibitor that suppresses the immune-mediated destruction of the lacrimal tissue and actively stimulates tear production. Because the underlying autoimmune disease is managed rather than cured, cyclosporine therapy is lifelong; stopping the medication will result in a rapid relapse of inflammation and tear loss.

For cases that are refractory (unresponsive) to cyclosporine, veterinarians escalate therapy by adding compounded tacrolimus (0.02% to 0.03% drops or ointment). Tacrolimus is a more potent calcineurin inhibitor that is used off-label in veterinary medicine.

In a review of the openFDA animal adverse-event dataset (2026-07-05 snapshot), there are 130 reports naming "Cyclosporine (Ophthalmic)" and 18 reports naming "Tacrolimus (Ophthalmic)" as active ingredients. These figures are spontaneous reports and do not prove causality, but they highlight the overall safety and regulatory visibility of these ophthalmic therapies compared to systemic administrations.

Untreated KCS leads to corneal vascularization, severe pigmentary keratitis (where dark pigment covers the eye like a window shade), painful corneal ulcers, corneal rupture, and permanent blindness. In end-stage refractory cases, a surgical procedure called parotid duct transposition (PDT) can redirect saliva from the salivary glands to lubricate the eye, though medical management is always preferred.

What does a low Schirmer tear test actually mean?

To understand how dry eye is diagnosed and staged, it is necessary to examine the composition of the canine tear film. The tear film is not just simple water; it is a complex, three-layered structure that coats the surface of the eye:

Outer Lipid Layer: Produced by the meibomian glands along the eyelid margins. This oily layer prevents the evaporation of the underlying water layer.
Middle Aqueous Layer: Produced by the orbital lacrimal gland (60–70% of volume) and the gland of the third eyelid (30–40% of volume). This water-rich layer hydrates the cornea, flushes away foreign material, and contains essential oxygen, nutrients, and immunoglobulins.
Inner Mucin Layer: Produced by the conjunctival goblet cells. This mucous layer helps the tear film adhere evenly to the hydrophobic corneal epithelium.

Keratoconjunctivitis sicca is a deficiency in the middle aqueous layer. When aqueous production falls, the tear film fails. The remaining lipid and mucin layers accumulate as a thick, stringy, mucoid or mucopurulent (pus-like) discharge. This discharge is often mistaken for conjunctivitis, but it is actually the eye's desperate attempt to lubricate itself with mucus in the absence of water.

Normal Tear Film:  [Lipid Layer] ──► [Aqueous Layer (Water)] ──► [Mucin Layer] ──► Clear Cornea
KCS Tear Film:     [Lipid Layer] ──► [AQUEOUS DEFICIENCY]     ──► [Excess Mucin] ──► Irritated, Goopy Cornea

The definitive diagnostic tool is the Schirmer tear test (STT). The test is performed by placing a thin, sterile, graduated paper strip into the lower conjunctival sac (the pocket between the lower eyelid and the eyeball) of each eye. The strip remains in place for exactly 60 seconds, and the moisture from the tears migrates up the strip by capillary action.

It is critical that the STT is performed before any other drops, washes, or topical anesthetics are applied to the eye, as these substances will artificially alter the tear measurement.

Ophthalmic clinicians interpret the STT results using the following standardized thresholds:

Normal (15 mm/minute or greater): Indicates adequate aqueous tear production. The eye is producing enough fluid to maintain corneal health.
Borderline (11 to 14 mm/minute): Indicates early, mild, or subclinical KCS. While the dog may not show severe clinical signs yet, the tear film is compromised. Close monitoring and follow-up testing are recommended, especially in predisposed breeds.
Mild-to-Moderate KCS (6 to 10 mm/minute): Indicates active dry eye. The cornea is experiencing desiccating stress, and clinical signs (redness, mucoid discharge, squinting) are typically present. Ophthalmic therapy should be initiated immediately.
Severe KCS (5 mm/minute or lower): Indicates a critical tear deficiency. The cornea is at high risk for ulceration, scarring, and pigment accumulation. Aggressive therapy is required.

In addition to the STT, veterinarians perform a fluorescein stain test on any dog suspected of KCS. Because dry eye leaves the cornea unprotected, friction from the eyelids can easily cause corneal ulcers (abrasions). The fluorescein dye adheres to exposed corneal stroma, highlighting ulcers under a cobalt blue light, which dictates whether topical steroids must be avoided.

Why is cyclosporine (Optimmune) a lifelong medication?

The vast majority of canine KCS cases (estimated at 75–80%) are immune-mediated. The dog's immune system experiences a loss of tolerance, and T-lymphocytes infiltrate the orbital lacrimal gland and the gland of the third eyelid. This chronic lymphocytic-plasmacytic infiltration leads to progressive inflammation, tissue destruction, and eventual atrophy of the tear-producing cells.

The Mechanism of Cyclosporine

Cyclosporine (specifically cyclosporine A) revolutionized the treatment of canine KCS. Prior to its introduction, KCS was managed poorly with frequent applications of artificial tears and mucolytic drops, which only provided temporary relief.

Cyclosporine is a lipophilic cyclic polypeptide that acts as a potent immunomodulator:

Calcineurin Inhibition: Inside T-cells, cyclosporine binds to a cytosolic protein called cyclophilin. This complex inhibits calcineurin, a calcium-dependent phosphatase enzyme.
IL-2 Suppression: Calcineurin is required to activate the nuclear factor of activated T-cells (NFAT), which transcribes interleukin-2 (IL-2). By blocking this pathway, cyclosporine stops the production of IL-2.
Halting T-Cell Activation: IL-2 is the primary cytokine responsible for the activation and multiplication of T-lymphocytes. Suppressing IL-2 halts the autoimmune attack on the lacrimal glands.
Direct Lacrimal Stimulation: In addition to its anti-inflammatory effects, cyclosporine has a direct prolacrimostimulatory effect, directly triggering the lacrimal cells to secrete tears.

The Regulatory Status of Optimmune

Pet owners must understand the difference between FDA-approved veterinary drugs and compounded alternatives. Optimmune Ophthalmic Ointment (cyclosporine 0.2%), manufactured by Merck Animal Health and approved under NADA 141-052, is the only FDA-approved veterinary formulation of cyclosporine for ophthalmic use in dogs.

The approval of Optimmune was supported by rigorous safety and efficacy data reviewed by the FDA Center for Veterinary Medicine. It is formulated in a specialized sterile petrolatum base that maximizes the contact time of the drug on the corneal surface.

While oral cyclosporine is used systemically for atopic dermatitis in dogs (marketed as Atopica for Dogs), the systemic capsules do not treat dry eye effectively unless given at doses that carry high risks of systemic side effects. The local, topical route via Optimmune is mandatory for KCS.

Why Treatment is Lifelong

Because KCS is an autoimmune disease, the genetic predisposition to attack the lacrimal glands remains with the dog forever. Cyclosporine does not cure the genetic defect; it merely suppresses the immune response and supports the surviving lacrimal tissue.

If an owner stops administering Optimmune because the dog's eyes look clear and the STT values have returned to normal, the drug concentration in the eye will drop. Within days to weeks, the T-lymphocytes will re-infiltrate the lacrimal glands, resuming the inflammatory destruction.

If this cycle of stopping and starting therapy is repeated, the lacrimal tissue will eventually undergo complete, irreversible fibrosis. Once the tear-producing cells are dead and replaced by scar tissue, no amount of cyclosporine can stimulate tear production. Therefore, Optimmune must be administered daily for the remainder of the dog's life.

When does the vet switch to tacrolimus, and why is it 'compounded'?

While Optimmune is highly effective, approximately 20% to 25% of dogs with KCS show an inadequate response to cyclosporine 0.2% ointment. In these refractory cases, the veterinary clinician will escalate medical therapy.

The Switch to Tacrolimus

Tacrolimus (formerly known as FK-506) is a macrolide lactone immunomodulator derived from the bacterium Streptomyces tsukubaensis. Like cyclosporine, tacrolimus is a calcineurin inhibitor that blocks T-cell activation and IL-2 transcription. However, it is structurally distinct and highly potent:

Increased Potency: Tacrolimus is estimated to be 10 to 100 times more potent than cyclosporine on a molecular level.
Refractory Efficacy: In a peer-reviewed comparative study by Radziejewski & Balicki (2016), tacrolimus eye drops produced improvements in Schirmer tear test values and clinical signs comparable to cyclosporine eye drops in dogs with KCS, and clinical consensus reserves tacrolimus for cyclosporine-refractory cases.
Corneal Clearing: Tacrolimus is highly effective at reducing corneal vascularization and pigmentary keratitis, helping to clear the cloudy surface of the eye.

The Compounding Requirement

Unlike cyclosporine, there is no FDA-approved veterinary ophthalmic formulation of tacrolimus. There is also no human-approved ophthalmic tacrolimus product in North America.

To use tacrolimus for a dog's eyes, a veterinarian must write a prescription to a licensed veterinary compounding pharmacy. The pharmacy compiles the drug from bulk substance into a sterile ophthalmic solution (typically 0.02% or 0.03% concentration in an oil base, such as olive oil or medium-chain triglyceride oil) or a sterile ointment.

Compounded medications are essential in veterinary medicine, but they carry distinct considerations:

Lack of FDA Oversight: Compounded drugs are not reviewed by the FDA for safety, efficacy, stability, or consistency.
Quality Control: The sterility and concentration of the active ingredient depend entirely on the quality standards of the compounding pharmacy. It is recommended to use pharmacies that are PCAB-accredited (Pharmacy Compounding Accreditation Board).
Off-Label Status: Tacrolimus must be used strictly off-label under the rules of the Animal Medicinal Drug Use Clarification Act (AMDUCA).

Comparing first-line and second-line therapies:

Feature	Optimmune (Cyclosporine 0.2%)	Compounded Tacrolimus (0.02%–0.03%)
FDA Approval Status	FDA-Approved (NADA 141-052); reviewed for safety and stability.	Off-label; compounded by specialty pharmacies.
Clinical Position	First-line choice for chronic KCS and chronic superficial keratitis.	Second-line choice; reserved for cyclosporine-refractory cases.
Relative Potency	Standard calcineurin inhibitor potency.	10 to 100 times more potent than cyclosporine.
Typical Formulation	Sterile petrolatum-based ointment (sterile tube).	Sterile oil-based drops or petrolatum ointment.
Availability	In-stock at most primary clinics and distributors.	Ordered custom from specialty compounding pharmacies.
Cost Profile	Moderate (approx. $60–$90 per 3.5g tube).	Variable (approx. $40–$70 per bottle, plus shipping).

What happens if dry eye is left untreated?

Choosing not to treat KCS is not an option for a responsible pet owner. Dry eye is an intensely uncomfortable condition, and the long-term pathological consequences are severe.

Without the lubricating, nourishing, and protective aqueous layer of the tear film, the cornea is subjected to constant friction from the eyelids. The surface of the eye becomes desiccated and hypoxic (deprived of oxygen). This chronic trauma triggers a progressive sequence of pathological changes:

Conjunctival Hyperemia and Blepharospasm: The conjunctiva becomes bright red and inflamed. The dog squints and rubs at their eyes due to the constant sensation of sand or grit in the eye.
Corneal Vascularization: In an attempt to deliver oxygen and nutrients to the starving cornea, the body grows new blood vessels (neovascularization) across the normally transparent corneal surface.
Corneal Ulceration: The fragile corneal epithelium tears and rubs away, creating painful ulcers. Because tears contain essential wound-healing factors, KCS ulcers heal very slowly and are prone to getting infected by opportunistic bacteria.
Descemetocele and Corneal Rupture: Deep corneal ulcers can erode down to Descemet's membrane (the innermost layer of the cornea). If this membrane ruptures, the fluid inside the eye escapes, leading to collapse of the globe, severe intraocular infection (endophthalmitis), and loss of the eye.
Pigmentary Keratitis: To protect the chronically irritated cornea, the body deposits dark melanin pigment across the eye. Over months and years, this pigment thickens and covers the cornea. This acts like a black curtain, permanently blocking the dog's vision.

Untreated KCS 
    │
    ▼ (Corneal Desiccation)
Corneal Friction & Hypoxia ──► Corneal Ulcers ──► Descemetocele ──► Corneal Rupture (Loss of Eye)
    │
    ▼ (Chronic Irritation)
Corneal Vascularization & Pigmentary Keratitis ──► Permanent Blindness

For dogs suffering from both dry eye and elevated intraocular pressure, the compounding corneal damage is severe. Ophthalmic clinicians must carefully balance these therapies, referencing guidelines like the glaucoma bilateral prophylaxis rule to avoid drug interactions or secondary corneal complications.

Which dogs get KCS most often?

While KCS can affect any dog, genetic studies have identified a strong breed predisposition. The disease is predominantly diagnosed in:

West Highland White Terrier: The "poster child" for canine KCS. They have an extremely high prevalence of immune-mediated dry eye, which is often severe and requires early, aggressive therapy.
Cocker Spaniel (American and English): Highly predisposed. In these breeds, KCS is sometimes associated with an inherited developmental defect of the lacrimal tissue or concurrent cherry eye (prolapse of the gland of the third eyelid).
English Bulldog: Bulging eyes (macropalpebral fissure) increase the evaporation of tears, exacerbating KCS.
Cavalier King Charles Spaniel: Often diagnosed with a severe, congenital form of KCS associated with a genetic syndrome known as "Curly Coat Dry Eye Syndrome" (ichthyosiform dermatosis).
Pug, Shih Tzu, Lhasa Apso: Brachycephalic (flat-faced) breeds are highly vulnerable. Their facial anatomy prevents complete eyelid closure (lagophthalmos), meaning the central cornea is exposed to constant drying even with normal tear production. KCS in these dogs rapidly leads to central corneal pigmentation and ulceration.

What if drops stop working? Surgical Parotid Duct Transposition (PDT)

If a dog with severe KCS (STT <= 2 mm/minute) fails to respond to maximum medical therapy (both cyclosporine and tacrolimus), and the cornea is consistently ulcerating, the veterinary ophthalmologist may recommend surgery.

The primary surgical option is parotid duct transposition (PDT).

The Principle: Saliva and tears share similar lubricating properties. The parotid salivary gland sits below the ear, and its duct (the parotid duct) travels across the cheek to empty saliva into the mouth near the upper premolar teeth.
The Procedure: Under general anesthesia, the surgeon dissects the opening of the parotid duct from the mouth and tunnels it under the skin, redirecting the duct to empty into the conjunctival sac of the eye.
The Outcome: The parotid gland now pumps saliva onto the surface of the eye. This provides a continuous source of aqueous lubrication.
The Complications: Saliva is not identical to tears. It is higher in calcium and mineral content, which can deposit as a white, chalky film on the cornea, requiring long-term topical chelating drops (like EDTA). Furthermore, the dog will "tear" (salivate) onto their face whenever they smell or eat food, requiring diligent skin care to prevent salivary dermatitis.

Safety and Adverse Event Data: openFDA Snapshot

When administering lifelong topical medications, safety is a key concern. In our analysis of the openFDA animal adverse-event dataset (reproducible from the 2026-07-05 database snapshot), we evaluated the reporting volume for these ophthalmic immunomodulators:

Cyclosporine (Ophthalmic): 130 reports were recorded.
Tacrolimus (Ophthalmic): 18 reports were recorded.

[!NOTE] These figures represent spontaneous, voluntary reports submitted to the FDA. They do not represent adverse-event rates or establish a causal relationship. A report simply means an owner or veterinarian noted a clinical sign after drug administration.

The low reporting volume for the ophthalmic formulations is encouraging, especially when compared to systemic medications. For comparison, systemic oral cyclosporine (Atopica for Dogs), which is absorbed throughout the body to treat atopic dermatitis, has 16,537 reports under "Cyclosporine" and 4,795 reports under "Cyclosporine A" in the same openFDA snapshot.

The localized route of topical ophthalmic ointment means the drug acts almost exclusively on the eye. Systemic absorption is minimal, so systemic side effects (like vomiting, diarrhea, or immunosuppression) are extremely rare.

The most common reported adverse signs for Optimmune and compounded tacrolimus are localized:

Transient Blepharitis: Mild swelling or redness of the eyelids.
Ocular Discomfort: Mild squinting or rubbing at the eye immediately after ointment application, which usually resolves within a few minutes.
Periocular Alopecia: Mild hair loss around the eyelids, often caused by the greasy petrolatum base spreading onto the surrounding skin.

How much does lifelong KCS treatment cost per year?

Managing KCS is a financial commitment. Because therapy cannot be stopped, owners must budget for ongoing costs:

Optimmune Ointment: A 3.5g tube of Optimmune costs approximately $60 to $90. For a medium-sized dog receiving a 1/4-inch strip in both eyes twice daily, a tube lasts about 3 to 4 weeks. This translates to $720 to $1,080 per year in drug costs.
Compounded Tacrolimus: If escalated to tacrolimus, a 5ml bottle costs approximately $40 to $70 and lasts about 1 to 2 months, translating to $240 to $840 per year.
Veterinary Rechecks: Monitoring requires Schirmer tear tests and corneal staining at least 2 to 3 times a year, costing $150 to $300 annually.
Supportive Lubricants: Artificial tear gels (like hyaluronic acid or carbomer drops) are often used between immunomodulator doses, adding $100 to $200 per year.

Total estimated annual cost of managing dry eye range from $970 to $1,580 per year for a standard medical pathway.

FAQs

Is dry eye in dogs curable?

No. Immune-mediated KCS is a chronic, progressive autoimmune disease that is manageable but not curable. The T-lymphocyte attack on the lacrimal glands can be suppressed with medications like Optimmune, but the underlying disease remains. If medications are discontinued, the immune system will resume its attack, and the dry eye will return.

Can I use human dry-eye drops on my dog?

Over-the-counter human artificial tears (without preservatives) are safe to use as temporary lubricants to soothe a dog's eyes. However, they do not treat the underlying cause of canine KCS. Human medicated dry-eye drops (such as Restasis, which is 0.05% cyclosporine) are too weak for dogs; dogs require the veterinary-strength 0.2% cyclosporine formulation (Optimmune) to stimulate tear production.

How long does Optimmune take to work?

Optimmune typically takes 2 to 4 weeks of twice-daily administration to show a measurable increase in tear production on a Schirmer tear test. During this initial phase, veterinarians often prescribe concurrent artificial tear lubricants to keep the cornea protected.

Does dry eye cause blindness in dogs?

Yes. If left untreated, the chronic irritation of KCS causes the body to deposit dark melanin pigment across the cornea (pigmentary keratitis). Over time, this pigment covers the entire corneal surface, blocking light and causing permanent blindness. Untreated KCS also causes deep corneal ulcers that can rupture, leading to the loss of the eye.

Is tacrolimus safe for dogs?

Topical ophthalmic tacrolimus is highly safe for dogs when prepared by a licensed compounding pharmacy and administered under veterinary supervision. Because the drug is applied locally to the eye, systemic absorption is negligible. Local side effects are rare and typically limited to mild, transient squinting or eyelid redness.

Sources

FDA Center for Veterinary Medicine. (1995). Freedom of Information Summary: NADA 141-052 (Optimmune Ophthalmic Ointment). https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/583
DailyMed (NIH). (2024). OPTIMMUNE Ophthalmic Ointment (cyclosporine 0.2%) Product Label. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ee9c677-d86c-4f2f-9eec-6998f4394ae1
Dodi, P. L. (2015). Immune-mediated keratoconjunctivitis sicca in dogs. Journal of Small Animal Practice, 56(4), 223-228. https://pmc.ncbi.nlm.nih.gov/articles/PMC6067592/
Radziejewski, K., & Balicki, I. (2016). Comparative clinical evaluation of tacrolimus and cyclosporine eye drops for the treatment of canine keratoconjunctivitis sicca. Acta Veterinaria Hungarica, 64(3), 313-329. https://pubmed.ncbi.nlm.nih.gov/27653428/
Today's Veterinary Practice. (2016). Diagnosis and Treatment of Keratoconjunctivitis Sicca in Dogs. https://todaysveterinarypractice.com/ophthalmology/diagnosis-treatment-of-keratoconjunctivitis-sicca-in-dogs/
Veterinary Information Network (VIN) Veterinary Partner. (2023). Dry Eye (Keratoconjunctivitis Sicca) in Dogs and Cats. https://veterinarypartner.vin.com/doc/?id=4951823&pid=19239
openFDA. (2026). Animal Adverse Event Dataset (Ingredient-level reports). Snapshot dated 2026-07-05.

Vet Med Guide

Dry Eye in Dogs: Lifelong Cyclosporine, Compounded Tacrolimus, and Tear Tests